Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Artiva Biotherapeutics logo
$1.96 -0.09 (-4.39%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.99 +0.03 (+1.53%)
As of 05/30/2025 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Artiva Biotherapeutics Stock (NASDAQ:ARTV)

Key Stats

Today's Range
$1.88
$2.04
50-Day Range
$1.81
$3.64
52-Week Range
$1.78
$17.31
Volume
65,522 shs
Average Volume
171,209 shs
Market Capitalization
$47.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.40
Consensus Rating
Buy

Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Artiva Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

ARTV MarketRank™: 

Artiva Biotherapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 704th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Artiva Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Artiva Biotherapeutics' stock forecast and price target.
  • Short Interest

    There is no current short interest data available for ARTV.
  • Dividend Yield

    Artiva Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Artiva Biotherapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ARTV.
  • News Sentiment

    Artiva Biotherapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Artiva Biotherapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for ARTV on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artiva Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Artiva Biotherapeutics' insider trading history.
Receive ARTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTV Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

ARTV Stock Analysis - Frequently Asked Questions

Artiva Biotherapeutics' stock was trading at $10.08 on January 1st, 2025. Since then, ARTV stock has decreased by 80.6% and is now trading at $1.96.
View the best growth stocks for 2025 here
.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced its earnings results on Thursday, May, 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by $0.15.

Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at $12.00 per share.

Top institutional shareholders of Artiva Biotherapeutics include venBio Partners LLC (4.92%), Charles Schwab Investment Management Inc. (0.23%) and Nuveen LLC (0.20%). Insiders that own company stock include Yong-Jun Huh and Global Strategic Fund I Venbio.
View institutional ownership trends
.

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

Last Earnings
5/08/2025
Today
5/30/2025
Next Earnings (Estimated)
6/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARTV
Previous Symbol
NASDAQ:ARTV
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.40
High Stock Price Target
$21.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+889.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$251,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$47.75 million
Optionable
N/A
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:ARTV) was last updated on 5/31/2025 by MarketBeat.com Staff
From Our Partners